CMC Lead – Multispecific Antibodies
Shennon Biotechnologies
CMC Lead – Multispecific Antibodies
Shennon Biotechnologies
Develops precision T-cell engager immunotherapies
Shennon Biotechnologies is developing precision immunotherapies for solid tumors through an integrated technology platform spanning target discovery, ultra-high-throughput microfluidics-driven functional screening, computational therapeutic design and safety prediction. Where conventional discovery tests binders sequentially over months, Shennon's TCELERATOR platform profiles more than 10 million single-cell interactions at once, identifying functional leads in a single experiment. This unified engine is supported by proprietary human tumor datasets and an expanding network of academic and clinical collaborators. The Company is developing both antibody-based and TCR-based T-cell engagers designed to address surface and intracellular cancer targets. Its initial oncology pipeline includes programs in small cell lung cancer, ovarian cancer and hepatocellular carcinoma. ShennonBio is based in San Francisco.
Our lead program is a trispecific TCE with dual tumor antigen targeting for small cell lung cancer. We are looking for someone to own CMC for it end to end, from the handoff out of discovery through to IND.
This is a director-level role: hands-on and accountable for the work, not an executive building a function. The role reports on an interim basis to the Head of Research, pending the hire of the Chief Scientific Officer.
A VP or head of function, a people manager, or a full-time hire on day 1. Depth on the work matters more than the title.
Collaboration, ownership and authenticity.
Consulting agreement to start, with a monthly hours cap, since there is 1 program today. Remote is fine and we have no geographic preference at this stage. As further programs reach the same point, the role is intended to convert to a full-time permanent position, which at that point would be co-located in San Francisco.
Develops precision T-cell engager immunotherapies
Shennon Biotechnologies develops precision immunotherapies for solid tumors, focusing on T-cell engagers (TCEs). Its discovery platform combines target discovery, ultra-high-throughput microfluidic screening, computational design, and safety prediction, with the TCELERATOR system profiling over 10 million single-cell interactions. It differentiates itself by integrating large-scale functional screening with multi-target TCE formats (trispecific, antibody-based, and TCR-based) to identify safer, more effective candidates for solid tumors. The company aims to move from platform development to development-stage execution, advancing three programs (SBT-121, SBT-201, SBT-425) and pursuing ongoing fundraising and leadership to push toward clinical development.
Explore more opportunities at Shennon Biotechnologies